Immunotherapy A new frontier Candace S. Johnson, PhD Immunotherapy - - PowerPoint PPT Presentation

▶

Aug 22, 2022 209 likes •356 views

Immunotherapy A new frontier Candace S. Johnson, PhD Immunotherapy is the new focus in oncology Tipping point for cancer immunotherapy Major advances in the last 10 years Your immune system protects you against cancer Success

SLIDE 1

Immunotherapy “A new frontier”

Candace S. Johnson, PhD

SLIDE 2

Immunotherapy is the new focus in oncology

SLIDE 3

Tipping point for cancer immunotherapy

Major advances in the last 10 years

– Your immune system protects you against cancer – Success with vaccination against HPV (Gardasil) – Knowledge of the immune system has increased

SLIDE 4

The Immune System

SLIDE 5

20 40 60 80 100 120 140

Overall Survival (Months)

0.0 0.2 0.4 0.6 0.8 1.0

Cumulative Survival

Intraepithelial CD8+ TIL lowest tertile all others Log Rank test P=0.009

Median survival: 55 vs. 26 months

Roswell Park Study: Immune responses in ovarian cancer = improved survival

Sato et al, PNAS, 2005, 102:18538

SLIDE 6

Immune cell (T cell) Tumor cell

Immunotherapy – “living drug” not chemicals, a targeted answer to cancer:

http://www.theanswertocancer.org/

boosts

your immune system to help eliminate cancer cells

enhances

immune response by providing additional components

SLIDE 7

Cancer Immunotherapy

Major advances recently

– Several FDA approvals for a class of immunotherapies – “immune checkpoint blockers”. – Now approved for melanoma, lung, bladder, liver, kidney: and the list continues to grow.

SLIDE 8

Immunotherapy at RPCI: Leading the way

monoclonal antibodies

http://www.theanswertocancer.org/

ncolytic virus

checkpoint blockade adoptive T cell transfer cancer vaccine cytokine/immunomodulator

Not all immunotherapies are created equal
Which is the best immunotherapy for me?
Advanced next generation

SLIDE 9

Benefits of cancer immunotherapy

http://www.theanswertocancer.org/

Power to target cancer in a specific way Ability to work on many types of cancer

even those that do not respond to chemo or radiation

Potential for reduced side effects commonly associated with chemotherapy

e.g. nausea, vomiting, hair loss

Possibility for long-term remissions

SLIDE 10

Selection of trials conducted at Roswell Park: No cancer type is left behind

varian

cancer

I 243813 LUD2014-011 I 276015

melanoma

I 243813 LUD2014-011 PH 227012

prostate cancer

I 243813 LUD2014-011 PH 283216

breast cancer

I 243813 LUD2014-011 PH 253914

colon cancer

I 243813 LUD2014-011 I 274515

lung cancer

I 243813 LUD2014-011 PH 269015

leukemia lymphoma

PH 236713 I 248613 I 277115 I 215912 I 250113 I 191511 I 191511 I 191511 I 227712 PH 281816 I 258514 I 230612 I 283616 I 258514 I 258514 I 223912 I 258514 I 258514 I 258514 PH 251514 I 210611 PH 268215

checkpoint blockade

LUD2015-001 LUD2015-001 PH 280416

ncolytic

virus adoptive transfer cancer vaccines

I 288216

SLIDE 11

Next generation immunotherapies at Roswell Park: Generating T cells for adoptive transfer therapy

TCR = T cell receptor CAR = chimeric antigen receptor recognize and destroy tumor cells TCR CAR

receptor transfer

SLIDE 12

Recent FDA approval for first engineered T cell

SLIDE 13

Our expectations of clinical outcomes of immunotherapy

100% 0%

% of treated patients alive traditional therapies immunotherapies immunotherapies in combination Time

Traditional therapies: Lives extended, but responses often not durable. Disease progresses or recurs. Few lives ultimately saved. Immunotherapies: Patients with sufficient anti-cancer immunity achieve durable disease control. Many lives are saved.